Apellis Pharmaceuticals
APLS
APLS
203 hedge funds and large institutions have $4.08B invested in Apellis Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 74 increasing their positions, 57 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
17% more funds holding
Funds holding: 174 → 203 (+29)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.73% less ownership
Funds ownership: 80.92% → 80.19% (-0.73%)
Holders
203
Holding in Top 10
5
Calls
$126M
Puts
$84.1M
Top Buyers
| 1 | +$96.6M | |
| 2 | +$44.7M | |
| 3 | +$41.8M | |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$37.8M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$34.4M |
Top Sellers
| 1 | -$103M | |
| 2 | -$64.2M | |
| 3 | -$39.5M | |
| 4 |
Goldman Sachs
New York
|
-$27.2M |
| 5 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
-$23.8M |